Your browser doesn't support javascript.
loading
Leveraging CTSA hubs for rapid, large-scale, high-impact research: A case study during a global public health emergency.
Croker, Jennifer A; Valenti, Shannon; Baus, Holly Ann; Ford, Eric W; Mathias, David; Yasko, Laurel; McGaughey, Dan; Smith, Tony; Underwood, Katherine; Avolio, Jennifer; Sadtler, Kaitlyn; Memoli, Matthew J; Kimberly, Robert P; Reis, Steven E.
Affiliation
  • Croker JA; Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Valenti S; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Baus HA; LID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ford EW; Department of Health Care Organization, and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Mathias D; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Yasko L; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • McGaughey D; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Smith T; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Underwood K; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Avolio J; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
  • Sadtler K; Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894, USA.
  • Memoli MJ; LID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kimberly RP; Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Reis SE; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.
J Clin Transl Sci ; 7(1): e13, 2023.
Article in En | MEDLINE | ID: mdl-36755544
As the COVID-19 pandemic took hold in the USA in early 2020, it became clear that knowledge of the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among asymptomatic individuals could inform public health policy decisions and provide insight into the impact of the infection on vulnerable populations. Two Clinical and Translational Science Award (CTSA) Hubs and the National Institutes of Health (NIH) set forth to conduct a national seroprevalence survey to assess the infection's rate of spread. This partnership was able to quickly design and launch the project by leveraging established research capacities, prior experiences in large-scale, multisite studies and a highly skilled workforce of CTSA hubs and unique experimental capabilities at the NIH to conduct a diverse prospective, longitudinal observational cohort of 11,382 participants who provided biospecimens and participant-reported health and behavior data. The study was completed in 16 months and benefitted from transdisciplinary teamwork, information technology innovations, multimodal communication strategies, and scientific partnership for rigor in design and analytic methods. The lessons learned by the rapid implementation and dissemination of this national study is valuable in guiding future multisite projects as well as preparation for other public health emergencies and pandemics.
Key words

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Year: 2023 Type: Article